Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 32, Number 8—August 2026

Research Letter

Antibodies Cross-Reactive with Bundibugyo Virus in Ferrets Vaccinated with Ebola Virus Vaccine

Jordan Wight, Helene Schulz, and Logan BanadygaComments to Author 
Author affiliation: Public Health Agency of Canada, Winnipeg, Manitoba, Canada (J. Wight, H. Schulz, L. Banadyga); University of Manitoba, Winnipeg (L. Banadyga)

Main Article

Figure 2

Endpoint titers of EBOV glycoprotein– and BDBV glycoprotein–specific IgG in rVSV-EBOV– vaccinated ferrets (A) and controls (B) in study of antibodies cross-reactive with BDBV in ferrets vaccinated with EBOV vaccine. Serial dilutions of serum were assayed by indirect ELISA. Date shown are reciprocal endpoint titers exceeding the cut-off value of the mean plus 3 times the SD of the 1:400 dilution of prevaccination serum collected from all ferrets. Horizontal colored lines represent the mean reciprocal endpoint titers. The dashed line at a reciprocal endpoint titer of 400 represents the lower limit of detection of the assay. BDBV, Bundibugyo virus; EBOV, Ebola virus; rVSV-EBOV, recombinant vesicular stomatitis virus–based vaccine encoding the Ebola virus glycoprotein.

Figure 2. Endpoint titers of EBOV glycoprotein– and BDBV glycoprotein–specific IgG in rVSV-EBOV– vaccinated ferrets (A) and controls (B) in study of antibodies cross-reactive with BDBV in ferrets vaccinated with EBOV vaccine. Serial dilutions of serum were assayed by indirect ELISA. Date shown are reciprocal endpoint titers exceeding the cut-off value of the mean plus 3 times the SD of the 1:400 dilution of prevaccination serum collected from all ferrets. Horizontal colored lines represent the mean reciprocal endpoint titers. The dashed line at a reciprocal endpoint titer of 400 represents the lower limit of detection of the assay. BDBV, Bundibugyo virus; EBOV, Ebola virus; rVSV-EBOV, recombinant vesicular stomatitis virus–based vaccine encoding the Ebola virus glycoprotein.

Main Article

Page created: June 11, 2026
Page updated: July 27, 2026
Page reviewed: July 27, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external